GKOS (Glaukos Corporation) חוב לטווח קצר להון

Glaukos Corporation (GKOS) is protected by exclusive patents for microstents and maintains a powerful influence in ophthalmology under strict FDA oversight. This price chart on GURU.Markets shows the shares demonstrating a metric of 0.01. The business relies on advanced engineering of miniature implants for glaucoma therapy. The company is currently implementing the iDose TR system, radically updating global standards for microsurgical intervention in the ocular environment.

The high-tech status of Glaukos Corporation (GKOS) as a leader in glaucoma therapy ensures strong market resilience, which is reflected in the current value of 0.01. By analyzing changes in short-term debt relative to equity, an investor can track the daily price action of short-term liabilities (up to one year), allowing for the rapid diagnosis of liquidity risks and confirmation of the fundamental reliability of the company's financing structure.